TABLE 4.

Cumulative fractions of response of four dalbavancin dosing regimens against MIC distribution of 801 Staphylococcus aureus clinical isolates causing bone and joint infections in U.S. and European hospitals (14) at the three PK/PD targets^a

Dalbavancin regimen (mg) at day (d)	CFRs of MSSA isolates (n = 534) at:			CFRs of MRSA isolates (n = 267) at:
	fAUC24h/MIC > 27.1	fAUC24h/MIC > 53.3	fAUC24h/MIC > 111.1	fAUC24h/MIC > 27.1	fAUC24h/MIC > 53.3	fAUC24h/MIC > 111.1
1,500 d1 + 1,500 d8
At d21	100	100	99.74	100	100	99.82
At d28	100	99.74	97.29	100	99.82	97.14
At d35	99.77	98.17	90.51	99.86	98.12	90.00
At d42	99.60	95.29	80.31	99.08	95.09	79.22
At d49	98.09	91.04	47.97	98.09	90.04	45.26
At d56	95.49	69.19	22.74	95.19	67.33	21.44
1,500 d1 + 1,500 d8 + 500 d36
At d42	100	100	99.43	100	100	99.46
At d49	100	99.47	93.36	100	99.51	92.79
At d56	99.67	96.34	77.32	99.74	96.09	75.93
1,500 d1 + 1,500 d8 + 1,000 d36
At d49	100	99.87	98.40	100	99.96	98.32
At d56	100	99.12	91.53	99.97	99.13	90.86
At d63	99.43	95.73	76.67	99.48	95.47	75.30
1,500 d1 + 1,500 d8 + 1,500 d36
At d56	100	100	98.00	100	100	97.97
At d63	100	99.68	96.25	100	99.75	95.97
At d70	99.17	93.43	61.1	99.19	92.93	58.93

^aCFR, cumulative fraction of response; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; d, day. Numbers in bold identify desirable CFRs ≥90%.